看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: U; D2 Y3 {$ \; a
( ?0 x5 |$ _& v
, ~. Z6 `& q; u0 _9 _9 t sCurrently available feasibility data for possible combination strategies. |/ a/ v2 C+ `2 S9 a
————————————————————————————————
9 G7 e3 g1 x. f" F. d, RCombination Feasibility according to preliminary data 8 U. R) l% k3 T1 ], e4 P' G, Z
——————————————————————————————————
" T0 W8 {' ~" P8 |' Q) LBevacizumab + sorafenib Yes, reduced dose ( ?2 v* c1 b7 b: O
Bevacizumab + sunitinib† No
5 C' F6 i+ A- DBevacizumab + temsirolimus Yes 4 n, V6 w$ w$ o6 I6 ~9 N
Bevacizumab + everolimus Yes
6 h/ m- H, R6 z! k" A, ?, ~1 iSorafenib + sunitinib ?
0 l' b/ ?5 b6 HSorafenib + temsirolimus Yes, reduced dose
+ X$ d* C: G1 {% p6 j6 }Sorafenib + everolimus Yes, reduced dose
6 k: o+ T( o) Y- B M0 bSunitinib + temsirolimus† No , d V) g& B6 ]- w
Sunitinib + everolimus ?
4 E) X) ^1 `, ?; [" E+ E$ N8 iTemsirolimus + everolimus ? 1 K$ [/ G' b; G7 u: ~
————————————————————
+ B+ X9 w* H( z4 j; F" R†Led to US FDA warning.( T1 P: c- `0 u6 `
?: As yet unattempted combination./ i* M9 ]. V+ S' D G" s
|
显身卡
